GSK

brain
Biotech

Alector halves staff after GSK-partnered antibody fails in ph. 3

To pivot away from latozinemab, the Bay Area biotech is laying off 49% of its staff, while the company’s R&D head is resigning effective Dec. 22.
Darren Incorvaia Oct 22, 2025 11:23am
Businessman climbing steps to pluck a star from the sky

GSK unveils pivotal data on oral antibiotic ahead of FDA filing

Oct 21, 2025 10:55am
ESMO Berlin 2025

ESMO: The ADC 'rollercoaster' rides on with next-gen meds

Oct 21, 2025 3:00am
GSK ESMO

GSK says 'stay tuned' for more ADC data as Hansoh posts 49% ORR

Oct 19, 2025 10:40am
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin
Favicon Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am
abstract concept of woman or girl

As 2 CEOs depart, life sciences face leadership void for women

Oct 3, 2025 11:22am